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Abstract
Neuroblastoma (NB) is a neural crest–derived childhood tumor characterized by a remarkable phenotypic diversity,
ranging from spontaneous regression to fatal metastatic disease. Although the cancer stem cell (CSC) model pro-
vides a trail to characterize the cells responsible for tumor onset, the NB tumor-initiating cell (TIC) has not been iden-
tified. In this study, the relevance of the CSC model in NB was investigated by taking advantage of typical functional
stem cell characteristics. A predictive association was established between self-renewal, as assessed by serial sphere
formation, and clinical aggressiveness in primary tumors. Moreover, cell subsets gradually selected during serial
sphere culture harbored increased in vivo tumorigenicity, only highlighted in an orthotopic microenvironment. A
microarray time course analysis of serial spheres passages from metastatic cells allowed us to specifically “profile”
the NB stem cell–like phenotype and to identify CD133, ABC transporter, and WNT and NOTCH genes as spheres
markers. On the basis of combined sphere markers expression, at least two distinct tumorigenic cell subpopulations
were identified, also shown to preexist in primary NB. However, sphere markers–mediated cell sorting of parental
tumor failed to recapitulate the TIC phenotype in the orthotopic model, highlighting the complexity of the CSC model.
Our data support the NB stem–like cells as a dynamic and heterogeneous cell population strongly dependent on
microenvironmental signals and add novel candidate genes as potential therapeutic targets in the control of high-
risk NB.
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Introduction
Neuroblastoma (NB) is a pediatric cancer originating from neural
crest–derived sympathoadrenal progenitors. This disease displays a
considerable heterogeneity, reflected in the clinical outcome, ranging
from spontaneous regression to extreme malignancy [1–3]. Moreover,
NB exhibits a wide range of differentiated phenotypes, from undiffer-
entiated tumors to tumors containing a neural crest–derived differenti-
ated cell range [4].
Heterogeneity within cancer cell populations is common. However,
whether it results from functional cellular hierarchy for malignancy, as
proposed by the cancer stem cell (CSC) model, or from clonal evolution
within the tumor is still a matter of intensive debate. In the CSC model,
tumors are exclusively sustained by a minor subpopulation of tumor-
initiating cells (TICs) [5–7]. This hierarchical stem cell model gained
considerable attractiveness by providing a likely explanation for the mul-
tiple treatment failures and ideal cellular targets to definitively eradicate
refractory tumors [5,8,9]. However, because stem cell–like cells have only
been convincingly identified in a limited number of tumor types, the
TIC model has been increasingly challenged [10]. The possibility that
such model may not apply to all solid tumors or may reveal to be con-
siderably more complex in some cancers is now suggested [11,12].
Because of its embryonal origin and heterogeneity, NB tumor qualifies
as a pertinent model to explore functional cellular hierarchy in solid
tumors. In addition, rare cells expressing neural crest stem and progenitor
cells markers were identified within NB tissues and cell lines, suggesting
the existence of NB CSC . However, very little is known on the existence
and phenotype of NB-TICs. Moreover, none of the markers defined to
prospectively identify functional TICs in several adult hematological and
solid malignancies apply for putative NB-TICs identification. Investi-
gators have therefore turned to functional stem cell–like characteristics
such as self-renewal (serial sphere formation), tumorigenicity (in vivo
serial tumor engraftment), and drug resistance (side population, drug sur-
vival) to isolateNB-TICs. Thus, Hansford et al. [13] and Smith et al. [14]
have isolated highly tumorigenic, drug-resistant sphere-forming cell lines
from NB metastatic bone marrow based on their capacities to self-renew
and differentiate toward distinct lineages.
Besides, well-characterized NB cell lines are known to recapitulate
the heterogeneity observed in tumors, and some of them were shown
to display stem cell–like characteristics. Thus, a highly tumorigenic
“side population” of cells capable to specifically efflux a Hoechst dye
was isolated from NB cell lines [15–17]. However, no specific gene
expression profiles have been formerly identified for NB-TICs either
in primary tumors or in NB cell lines.
To characterize representative phenotypes for self-renewal and
tumorigenicity, we performed a microarray time course analysis of
serial sphere passages obtained from patient bone marrow metastatic
NB cells. Such a dynamic and original analysis revealed a list of NB
sphere-associated genes that crossed with neural crest (NCC) and neu-
ral stem cell (NSC) genes, essentially implicated in developmental and
cell differentiation pathways [18–21]. Moreover, the sphere-associated
gene expression profiling combined with in vivo assay indicated that
NB-TICs most likely represent a heterogeneous cell population, whose
phenotype is strongly dependent on the direct microenvironment.
Materials and Methods
Isolation of NB Primary Cells
The tumor material was collected from a cohort of 10 NB patients,
diagnosed at the Hemato-oncology Unit of the University Hospital of
Lausanne (Switzerland), after informed consent and in agreement with
local institutional ethical regulations. Tumor tissues were processed
(within 24 hours after resection) in a single-cell suspension by me-
chanical dissociation in phosphate-buffered saline containing 0.01 mg/ml
collagenase II (Invitrogen, Carlsbad, CA; http://www.invitrogen.com)
and 0.1 mg/ml DNaseI (Roche Diagnostics, Basel, Switzerland; http://
www.roche-applied-science.com) for 30 minutes at 37°C, followed
by filtration through CellTricks (50 μm; Partek, Inc, St Louis, MO;
http://www.partek.com).
NB Genomic Profile Analysis
The genetic type of NB tumors was determined on biopsies with
a tumor cell content superior to 60% either by array comparative ge-
nomic hybridization (CGH; Curie Institute, Paris, France) as described
[22] or at the Agilent platform from the Genetic Division, University
Hospital, Lausanne [23]. Alternatively, fluorescent in situ hybridization
for the 1p, 2p, 7p and 7q, 11q, and 17q regions was performed [24].
In Vivo Studies
All animal experiments were carried out with athymic Swiss nude
mice (BALB/C nu/nu) in accordance to the European Community
guidelines (directive no. 86/609/CEE). NB cells isolated from involved
bone marrow aspirations or NB patient samples xenografts were used.
In heterotopic assays, 104 cells in Dulbecco modified Eagle medium
(DMEM)/F12 and BD Matrigel Basement Membrane matrix (1:1;
BD Biosciences, San Diego, CA; http://www.bdbiosciences.com) were
subcutaneously (s.c.) injected inmice flanks. In orthotopic assays, 104 cells
in phosphate-buffered saline were implanted in the adrenal gland as pre-
viously described [25]. Tumor intake and growth were followed up using
calipers every 3 days for s.c. tumors or every 2 weeks by ultrasound im-
aging to follow orthotopic growth (Lausanne Cardiovascular Assessment
Facility). Macroscopic metastases were evaluated by gross examination.
Immunohistochemistry
Standard hematoxylin and eosin (H&E) and immunohistostaining
procedures were performed on paraffin-embedded tissues, using mouse
monoclonal anti-human p75 (clone ME20.4), rabbit polyclonal anti-
human CD31 (Thermo Fisher Scientific, Waltham, MA; http://
www.thermofisher.com), and mouse monoclonal anti-human Ki67
(clone MIB-1; Dako, Carpinteria, CA; http://www.dakousa.com).
Cell Lines and Sphere Culture Conditions
NB cell lines, including LAN-1 [26] and SK-N-BE(2)C [27], were
grown in DMEM containing 10% fetal calf serum (Sigma-Aldrich,
St Louis, MO; http://www.sigma-aldrich.com), 100 U/ml penicillin,
and 10 μg/ml streptomycin (Invitrogen). The NB1-C cell line was
established by plating the dissociated NB1 cell suspension in neural
basic medium (DMEM/F12 supplemented with penicillin/streptomycin,
2% B27 [Invitrogen], human recombinant basic fibroblast growth
factor [FGF; 20 ng/ml; Peprotech, Rocky Hill, NJ; http://www.
peprotech.com], and EGF [20 ng/ml; Peprotech]).
NB sphere culture was performed in neural crest sphere medium,
prepared as described [28,29], and cultured in poly(2-hydroxyethyl
methylacrylate) (16 mg/ml in EtOH; Sigma)–coated six-well culture
plates to prevent cell adhesion. NB cells (2-8 × 104 cells/ml) were plated,
and spheres were passed every 7 to 10 days by dissociation in 0.05%
trypsin-EDTA (Invitrogen) and filtration in CellTricks (50 μm; Partek)
to obtain a single-cell suspension. This plating (104 cells/500 μl neural
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crest sphere medium in quadriplicates) procedure was serially repeated
to assay for self-renewal.
Immunoblot Analysis
Protein extracts were prepared as already described [30,31] with
a modified NP40 lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM
NaCl, 1% NP40). Extracts (50 μg) were loaded on 10% SDS-PAGE
and transferred on nitrocellulose membranes. Blots were labeled
with rabbit polyclonal anti–c-myc antibody (N-262; Santa Cruz Bio-
technology, Heidelberg, Germany) and NCMII mouse monoclonal
anti–N-myc antibody [32]. Blots were revealed using secondary
goat antimouse–horseradish peroxidase antibody (Jackson Immuno-
Research, Suffolk, United Kingdom) or goat antirabbit immunoglob-
ulin G–horseradish peroxidase (Nordic Immunological Laboratories,
Tilburg, Netherlands). Bound antibodies were detected using the ECL
Advance Kit according to the manufacturer’s instructions (GE Health-
care, Chalfont St Giles, United Kingdom).
Cell Viability Assay
Cells (5 × 103) were plated 24 hours before treatment in 96-well
plates with 1 μg/ml doxorubicin (Sigma), 100 μg/ml etoposide (Sigma),
and 16 μg/ml cisplatin (Sigma) for 48 hours. Cell viability was mea-
sured in triplicate using MTS/PMS cell proliferation kit (Promega
Corp, Madison, WI; http://www.promega.com) according to the manu-
facturer’s instructions.
Total RNA Extraction and Gene Expression Profiling
Cells were lysed with TRIzol reagent (Invitrogen), and total RNA
was extracted twice with ultrapure phenol-chloroform-isoamyl alco-
hol (25:24:1) (Invitrogen) and purified using RNeasy MicroKit col-
umns (Qiagen, Hilden, Germany; http://www.qiagen.com). RNA
quality was verified by the Bioanalyzer 2100 (Agilent Technologies,
Santa Clara, CA; http://www.chem.agilent.com) before microarray
hybridization.
Expression profiling experiments were performed at the DNA
Array Facility Lausanne, University of Lausanne, using the Human Ge-
nome U133Plus 2.0 Affymetrix GeneChip Technology (Affymetrix,
Santa Clara, CA; http://www.affymetrix.com).
The Remote Analysis Computation for gene Expression data system
developed by the DNA Array Facility Lausanne was used for micro-
array data analysis [33]. All chips were normalized using the robust
multiarray analysis procedure [34]. Statistical analyses of differentially
expressed genes were performed using the “R” statistical version 2.0.1.
The statistical value for the “step” gene analysis has been calculated by
the formula: X = meanðs1 : s4Þ − s0
s:d:ðs1 : s4Þ + 0:5 with X = “step” statistics and mean(s1:s4) −
s0 = “step” change. A cutoff has been defined as the absolute value
of X = 3. P values associated with the fold change (fold change ≥ 2)
were corrected for multiple testing using the false discovery rate
method with the cutoff set at 5%.
Complementary DNA Synthesis and Semiquantitative
Real-time Polymerase Chain Reaction
Reverse transcription of total RNA was performed using random
primers and SuperScript II reverse transcriptase (Invitrogen). Sphere-
associated gene expression was assessed by real-time semiquantitative
polymerase chain reaction (PCR, ABI PRISM 7900 HT System; Ap-
plied Biosystems, Carlsbad, CA; http://www.appliedbiosystems.com)
with SYBR Green detection (Qiagen). The amount of PCR product
was divided by that of human HPRT1 using the ΔΔC t method. Am-
plification reactions were performed with specific pairs of primers for
CD133, EDNRB, GPR177, NOTCH3, MDR1, NOTCH2, ROBO1,
and ABCA1 transcripts (Supplementary Materials and Methods).
Flow Cytometry
Single-cell suspensions were processed and stained as described
[35] with CD133/1-APC (Clone AC133; Miltenyi Biotec, Bergisch
Gladbach, Germany; http//www.miltenyibiotec.com), MDR1-PE
(P-glycoprotein, clone UIC2; Beckman Coulter, Brea, CA; http://
www.beckmancoulter.com) and anti-GD2 clone 7A4 [36] anti-
bodies. For specific cell sorting, a total of 106 cells were analyzed
and sorted at 4°C by FACSAria II Cell Sorter (BD Biosciences).
Statistical Analysis
Statistical analyses were carried out using GraphPad Prism 4.0
(GraphPad Software, Inc, La Jolla, CA; http://www.graphpad.com/
prism). P < .05 was considered to represent significance. P < .01 and
P < .001 were interpreted to be highly significant.
Results
Clinical NB Xenografts as Models to Address
NB-TIC Populations
The availability of tumor material was guaranteed by in vivo serial
subcutaneous xenograft NB cell transplantations. Table 1 summarizes
the characteristics of the patients’ tumors included in the study, compris-
ing five stage 4 (one relapse, NB4), one stage 3 (after chemotherapy),
Table 1. Clinical and Biologic Characteristics of NB Samples.
Sample Sex Age at Diagnosis Stage (INSS) Specimen Type BM Infiltration NMYC Genetic Type Follow-up Risk Group Xeno. Tumor
NB1 M 10 mo 4 bm Yes NA B DOD HR Yes (p16)
NB2 F 44 mo 4 bm Yes NA B CR HR Yes (p10)
NB3 M 40 mo 4 pt Yes NA B DOD HR Yes (p1)
NB4 M 12 y 4 bm-rel Yes NA B DOD HR Yes (p5)
NB5 M 24 mo 4 bm Yes A C/E CR HR Yes (p2)
NB6 F 58 mo 3 pt-pc No NA D AD HR No
NB7 F 1 d 4s bm Yes NA D CR LR/IR No
NB8 F 8 mo 4s cut No NA ND VGPR LR/IR ND
NB9 F 5 d 4s pt ND NA D VGPR LR/IR No
NB10 F 22 mo 3, GGN pt-pc No NA Flat CR LR No
NB1 to NB10 correspond to NB patients. Xeno. tumor: in vivo tumor growth capacity assessed by serial subcutaneous engraftments (px = passage number).
A indicates amplified MYCN locus; AD, alive with disease; bm, bone marrow; CR, complete remission; cut, cutaneous metastasis; DOD, dead of disease; F, female; GGN, ganglioneuroma; HR/IR/LR,
high/intermediate/low–risk group; INSS, International Neuroblastoma Staging System; M, male; NA, no amplification of MYCN locus; nd, not determined; pc, postchemotherapy; pt, primary tumor;
rel, relapse; VGPR, very good partial response.
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three stage 4s samples, and one ganglioneuroma. MYCN amplification
was detected inNB5 only, whereas the NB1 sample displayed a chromo-
somal gain in 8q identified as a c-MYC gain. Immunoblots for MYCN
and c-MYC were performed with protein extracts from the NB1-NB10
tumors. Data confirmed the MYCN and c-MYC overexpression in
NB5 and NB1, respectively (Figure W1). NB8 cells displayed an
increased MYCN expression in the absence of gene amplification. A
significant amount of c-MYC protein was also observed in the NB2
tumor without detectable amplification of the c-MYC locus. Array
CGH and fluorescent in situ hybridization were performed for all sam-
ples to determine the genetic type, as proposed [37].
To assay the tumorigenicity of patient samples, 1 million bone
marrow mononuclear cells from NB1, NB2, NB4, NB5, and NB7
were s.c. injected in nude mice. Fragments of primary tumor NB3,
NB6, NB9, and NB10 were s.c. grafted. Tumor growth was observed
in 5 of 10 samples, all were stage 4 tumors, with a time-of-tumor
detection varying from 40 to 60 days (Table 1).
Xenograft tumors were further serially propagated in nude mice
(Figure 1A). The maximum passage number varied from p1 (NB3)
to p16 for NB1, which showed the highest long-term in vivo serial pas-
sage capacity (Table 1). No tumor growth was obtained with stages 3
and 4s tumor samples NB6-NB10, even after 180 days of observation,
demonstrating that metastatic stage 4–derived NB samples displayed
the highest tumorigenicity.
The NB origin of the xenograft tumors derived from NB1 to NB5
samples was verified by array CGH analyses. NB1 p5 and NB2 p1
harbored the same NB typical alterations on the chromosomes 1, 4,
8, and 17 as the original primary tumors NB1 and NB2 (Figure 1, B
and C). Moreover, the strong cell surface expression of disialoganglio-
side (GD2) [38] measured in NB1, NB2, and NB4 xenograft tumors
confirmed their NB origin (Figure 1D). NB xenograft tumors also re-
capitulated the parental tumor histology and the intratumor heteroge-
neity as assessed by H&E staining and immunohistochemical staining
for Ki67, CD31, and CD271 (p75LNGFR) (Figure 1E). NB xenograft
Figure 1. Model for in vivo propagation of NB metastatic cells as xenografts. (A) The s.c. implantation of metastatic bone marrow cells
from NB1 patient generated the xenograft tumor NB1 p1, further serially transplanted up to p16, in Swiss nude mice. (B) Chromosomic
alterations (gains and losses) analyzed by array-CGH in NB1 and NB2 primary tumors. (C) Detailed array-CGH results for the indicated
chromosomes of NB1 p5 and NB2 p1 cells. Black arrowhead indicates identical chromosomic alterations in primary and xenograft
tumors. (D) FACS analysis of GD2 cell surface expression (black lines) and isotype control antibody (gray line). (E) H&E and immuno-
histologic staining for Ki67, CD31, and p75 markers (NB1 [primary tumor] and NB1 p6 xenografts).
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tumors were thus considered as stable NB tissue, suitable for further
phenotypic or functional studies.
High-risk Metastatic NBs Harbor Higher Sphere
Formation Capacity
NB1-NB4 xenografts and clinical samples listed in Table 1 were
analyzed for their ability to form serial spheres when propagated in a
serum-free medium (Figure 2A). Except NB3 cells, all stages 3 and
4 samples formed serial spheres; NB1 showed the highest capacity
for serial sphere formation (p5). NB7 to NB10 samples did not grow
as spheres (data not shown).
The tumor samples were assigned to low/intermediate (L/I) and
high-risk (HR) groups according to the current Children’s Oncology
Group (COG) criteria [39]. Tumors of the HR group displayed an
increased ability to generate serial spheres in culture compared with
tumors of the L/I group (P = .03; Figure 2B). These data supported
previous reports showing that HR NB tumors display enhanced self-
renewal characteristics [13].
NB cell lines are generally established from bone marrow aspira-
tions harvested in stage 4 patients (Figure 2C ) and propagated in
the presence of 10% serum, which is known to induce genetic and
epigenetic modifications in cancer cells, as opposed to serum-free con-
ditions [40]. We addressed the sphere-forming capacity of six NB cell
lines and NB1-C, a cell line established from the NB1 xenograft tumor
in serum-free medium (Figure 2D). All cell lines were able to grow
in sphere conditions up to high-passage numbers, such as NB1-C,
LAN-1, and SK-N-BE(2)C cells, although variability was observed
(Figure 2, D and E).
NB1 Sphere Cells (NB1-s) Are More Tumorigenic in the
Adrenal Microenvironment and Harbored an In Vitro
Increased Drug Resistance
Serial sphere formation has been proposed to enrich in cells with
TIC property in several cancer types. Considering the previously
mentioned results, we postulated that NB1 sphere cells represented
a relevant model to address the existence of NB-TICs.
The criterion standard for the assessment of TIC phenotype is a
serial in vivo orthotopic implantation of a putative NB-TIC popula-
tion. We thus compared the tumorigenicity of NB1 spheres cells
(NB1-s) with total NB1 cells orthotopically implanted. The tumor
intake between NB1-s and NB1, with 79% versus 40%, respectively,
was significantly different. The tumor volume (day 83) was also
Figure 2. The sphere-forming capacity is enriched in metastatic stage 4 NB cells. (A) Experimental model for serial spheres passage from
dissociated NB xenograft tumors in a serum-free medium (e.g., NB1). D indicates dissociation/replating. (B) In vitro sphere propagation
capacity of high-risk (High) and low/intermediate-risk NB groups (L/I). *P < .05, Student’s t test. (C) Characteristics of NB cell lines (adapted
from Thiele [77]). BM indicates bonemarrow; C, direct culture; DG, density gradient; unk, unknown. (D) Self-renewal assay for indicated NB
cell lines. (E) Microscopic observation (40× magnification) of secondary spheres.
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significantly larger in the NB1-s group (73.98 ± 36.61 mm3, n =
10) compared with the NB1 group (9.62 ± 2.16 mm3, n = 14) (P <
.01; Figure 3A). In contrast, when NB1 or NB1-s cells were hetero-
topically injected, no significant difference in tumor intake (6/6) or
detection time was measured (Figure 3B).
To validate the influence of the environment on tumor growth,
heterotopic implantations were repeated in the absence of Matrigel,
similarly to the orthotopic procedure (104 NB1 and NB1-s cells).
Surprisingly, no tumor intake was observed up to 133 days (data
not shown), indicating that factors present in the Matrigel were nec-
essary to support NB cell growth in the heterotopic site in contrast to
that in orthotopic conditions.
Because TICs have been defined as cells able to recapitulate the
parental tumor’s heterogeneity, the histology of the original patient
tumor NB1 and the subcutaneous (s.c.) and orthotopic NB1– and
NB1-s–derived tumors was analyzed according to the pathologic crite-
ria from the Shimada classification of NB tumors [41,42] (Figure 3C).
The NB1 tumor histology revealed diffused growth patterns with lobu-
lar architecture and presented as small round cells with scanty cytoplasm.
Typical for NB, a few Homer-Wright rosettes were present. The most
similar histology was observed in the orthotopic or subcutaneous
tumors. However, an undifferentiated histology and/or higher mitosis
karyorrhexis index (MKI) was observed in the orthotopic tumors. By
providing a favorable environment, orthotopic injections in the adrenal
Figure 3. NB1 sphere cells (NB1-s) harbored an increased tumorigenicity in orthotopic conditions and a resistance to chemotherapeutic
drugs. (A) In vivo orthotopic tumor intake (number of mice bearing tumor/total mice) and growth (mean tumor volumes ± SEM) of
NB1 and NB1-s cells. **P < .01 (two-way analysis of variance). (B) Detection time for subcutaneous tumors with a volume exceeding
250 mm3. (C) H&E staining of NB1 xenograft tumor and in vivo subcutaneous and orthotopic tumors derived from NB1 and NB1-s
cells. (D) Cytotoxic assay testing the drug resistance of LAN-1, LAN-1 spheres (LAN-1-s), and LAN-1R cells. Cell viability was measured
after 48 hours of indicated drug treatments. Bars are means ± SEM of two to three experiments. (E) Cytotoxic assay for drug resistance
in NB1 and NB1-s cells. Dissociated NB1 tumor and NB1 spheres were treated for 48 hours with the indicated drugs. ***P < .001
(Student’s t test).
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gland may thus highlight the tumorigenic properties of NB1-s cells while
preserving the histology of the tumor.
Evidences for the capacity for chemoresistance of CSCs have re-
cently emerged [43–45]. Therefore, we evaluated the sphere cell’s sen-
sitivity to conventional chemotherapeutic drugs in LAN-1 cell line and
in NB1 tumor cells. The doxorubicin-resistant LAN-1R counterpart
of the LAN-1 cell line [46] was included as a positive control for re-
sistance. Interestingly, LAN-1-s and NB1-s displayed a significantly
increased drug resistance compared with LAN-1 and NB1 cells, re-
spectively (Figure 3, D and E).
The Transcriptome Profile of NB1-s Reveals a Stem
Cell–like Phenotype
As NB1-s cells demonstrated enhanced in vivo tumorigenicity and
in vitro drug resistance, an original strategy to specifically “profile”
these functional TIC characteristics was chosen.
We postulated that, with serial sphere passages from NB1 sample
(NB1-s0), NB1 spheres (NB1-s1 to -s4) would progressively be en-
riched in cells with TIC properties. Hence, the successive NB1-s pas-
sage transcriptomes (s0-s4) were identified by a time course microarray
expression analysis (Figure 4A).
The differentially expressed genes in NB1-s were monitored using
two statistical approaches that reflected the two hypotheses of TIC
genes enrichment in the sphere cell population. Genes with a “linear”
expression evolution through s0 to s4 were selected, as well as genes
showing a drastic change or “step” evolution at s1. Both scenarios
allowed to in silico select genes with expression profile changes occur-
ring with successive sphere passages (Figure 4B).
The “linear” evolution analysis performed with NB1 and NB1-s
provided a list of 718 overexpressed and 540 underexpressed genes
(Table W1). However, the “step” evolution analysis showed 183 over-
expressed and 160 underexpressed genes. By overlapping those two
results, a global list of 1601 deregulated genes in NB1-s was obtained,
of which 700 were downregulated and 901 were upregulated genes
(Figure 4C and Table W1).
The highest upregulated genes identified in NB1-s corresponded to
the aldehyde dehydrogenase (ALDH1A2) gene and the leucine-rich
repeat-containing G protein–coupled receptor 5 (LGR5) gene, pre-
viously described as stem cell markers in human breast [47] and intes-
tine cancers [48], respectively. Interestingly, although NB1 sample was
collected before treatment, the ATP-binding cassette ABCB1 (MDR1)
multidrug resistance gene showed a seven-fold overexpression in NB1-s,
supporting the drug resistance of NB1-s cells shown in Figure 3E .
Finally, the NB1-s expression profile was enriched in genes involved
in essential attributes of stemness, including the NOTCH, WNT, and
growth hormone signaling pathways [20], as well as in neural crest
development and NB tumorigenesis (Table W2).
As NB originates from sympathetic nervous system progenitors, we
next postulated that NB-TICs were likely to display gene expression
profiles common with sympathetic nervous system progenitors, such
as NCCs and NSCs. The list of NB1-s differentially overexpressed
genes was crossed with two lists of published profiles: NCC-associated
genes, identified in neural crest stem cells (NCSCs, day E9.5 in the
mouse embryo) and neural crest–derived progenitor cells (NCDCs, day
E12), and NSC-associated genes [18,20] (Figure 4C and Table W1).
The overlap generated nine genes commonly upregulated in NCC,
NSC, and NB1-s, including the axon guidance receptor ROBO1 (6×);
GPR177 (10×), which regulates WNT proteins sorting and secretion
[49]; and NOTCH3 receptor (7×), which promotes cell self-renewal
and tumor formation [50–52]. In addition, 23 genes were found
commonly upregulated in NCC and NB1-s, including the CD133
(prominin-1) receptor (30×), VEGFC growth factor (9×), and FGF
receptor FGFR2 (3×). Finally, a list of 90 upregulated genes was iden-
tified in both NB1-s and NSC, among which two particularly relevant
genes emerged: EDNRB (33×) and ABCA1 (17×). EDNRA, receptor
for endothelin 1 (EDN1), has also been found 11-fold overexpressed
in NB1-s.
TIC Candidate Genes Are Overexpressed in Metastatic
NB-Derived Spheres
CD133, MDR1, EDNRB, GPR177, ROBO1, NOTCH3, and
ABCA1 genes were selected from the overlaps between NB1 tumor
sphere and NCC and NSC gene transcriptomes. Their relevance as po-
tential TIC genes and representativeness for self-renewal was addressed.
Sphere up-regulation of these genes was validated by real-time PCR and/
or FACS in secondary spheres derived from NB1, NB2, NB4, and
NB5 xenografts and from three NB cell lines, NB1-C, LAN-1, and
SK-N-BE(2)C, demonstrating high sphere formation capacity (Fig-
ure 4D). Interestingly, CD133,MDR1,GPR177, and ROBO1 were sig-
nificantly upregulated (fold change >1.5) or already highly expressed in
70% to 100% of the tested NB samples. In addition, EDNRB and
NOTCH3 were highly overexpressed in NB1-s2 (72.4× and 12.5×, re-
spectively), in NB2-s2 (EDNRB, 10.1×), and in NB4-s2 (NOTCH3,
5.2×), as well as highly expressed in NB1-C. ABCA1 overexpression
was restricted to NB1-s2 (9.9×) and NB1-C spheres (2.0×). NOTCH3
and ABCA1 gene expression did not increase in NB2 and NB4 sec-
ondary spheres. Most importantly, CD133 andMDR1 were constantly
increased in secondary spheres from most samples.
We therefore addressed the CD133 and MDR1 cell surface expres-
sion by FACS analysis (Figure 4E). The low or absent CD133 expres-
sion in NB2, NB4, LAN-1, and SK-N-BE(2)C cell lines as well as
their derived spheres was confirmed. However, CD133 expression in-
creased in NB1-s2 and was already very high in NB1-C and its derived
spheres. MDR1 harbored a variable but important expression in NB1,
NB2, and NB4, with a significant increase in the NB1-s2, NB2-s2,
and NB4-s2 cells. In NB cell lines, MDR1 remained very low in
NB1-C and NB1-C-s2 (3.5%-4.1%), whereas it slightly increased in
LAN-1 (from 70% to 86%) and was already high in SK-N-BE(2)C
(98%) and did not further increase.
These results highlighted a significant intersample heterogeneity and
the influence of serum-free conditions in either induction of sphere-
associated genes or selection of cells expressing these genes.
NB1-s Population Is Heterogeneous and Preexists in the
Parental Tumor
NB1-s cells was identified as a population with enriched self-
renewal and tumorigenic capacities and defined by a specific gene
expression profile.
CD133 was characterized by a very low expression in all patient
tumors analyzed and a “linear” increase evolution in the microarray
analyses of NB1-s. In contrast, MDR1 showed a “step” evolution in
NB1-s, suggesting that MDR1 and CD133 genes, although both
increased in spheres, might not be coexpressed, revealing a potential
cell heterogeneity in the sphere cell population.
To confirm this hypothesis, CD133high and CD133low- or MDR1high
and MDR1low-expressing cells were selected from NB1-s by FACS.
Expression of CD133, MDR1, GPR177, EDNRB, and ABCA1 was
measured on sorted cells by real-time PCR (Figure 5A). CD133high
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population contained enriched GPR177 and EDNRB gene expres-
sion, whereas the CD133low population was clearly highly enriched
in MDR1 expression. This observation confirmed the heterogeneity
in the NB1-s population and revealed at least two distinct populations
based on selected NB1-s markers.
To address the existence of several subpopulations in theNB1 tumor,
CD133high- and CD133low-sorted cells were analyzed for CD133,
MDR1, GPR177, EDNRB, ABCA1, and ROBO1 expression by real-
time PCR (Figure 5B). Results show that GPR177 and EDNRB were
significantly coselected within the CD133high population, whereas
a very low MDR1 expression was detected in both CD133high and
CD133low populations.
The reverse selection experiment was carried out in NB1 with
MDR1high and MDR1low sorted populations (Figure 5C). CD133 and
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GPR177 were preferentially expressed in the MDR1low subset. ABCA1
was, in contrast, slightly enriched in the MDR1high subset.
When doubleMDR1/CD133 cell sorting of theNB1 tumorwas per-
formed, three sorted populations, CD133highMDR1low cells (1.2% ±
0.2%), CD133lowMDR1high cells (15.4% ± 1.2%), and a major popu-
lation of CD133highMDR1high cells (83.2% ± 1.3%), were obtained
(Figure 5D). CD133/EDNRB/NOTCH3–expressing cells were
clearly coselected in the CD133high/MDR1low subset, whereas the
MDR1 gene was selected in the CD133low/MDR1high population
(Figure 5E ). These data confirmed the anticorrelated expression of
MDR1 and CD133 sphere-associated genes within the NB1 cells.
Altogether, these results supported the existence of at least two
distinct cell subsets with putative TIC characteristics in NB1-s,
CD133highMDR1low cells coexpressing EDNRB, GPR177, and
NOTCH3 and CD133lowMDR1high cells coexpressing ABCA1, as well
as their preexistence in the original NB1 sample.
CD133high and MDR1high NB Cell Populations Have
Different Tumorigenic Properties
To further address the functional heterogeneity of CD133/MDR1
sorted cell populations, their in vivo tumorigenic properties were
evaluated by orthotopic implantations (Figure 6).
Tumor intake observed for CD133high and CD133low populations
was not significantly different (Figure 6A). Adrenal tumors were de-
tected in two versus one of six mice in CD133high and CD133low
groups, respectively, with a contralateral ovarian metastasis in the
CD133high group (Figure 6B). FACS analysis of CD133high and
CD133low grown tumors revealed 6% and 21% CD133-positive cells,
respectively (Figure 6A) compared with the 6% CD133-positive cells
in the NB1 sample (Figure 4E ), showing that CD133low tumors
contained a higher number of CD133-positive cells than CD133high
and NB1 tumors. These observations indicate a high plasticity of these
cells in addition to their heterogeneity (Figure 6A). H&E staining
of tumors grown from CD133high and CD133low populations did
not reveal different histology, vascular, or differentiation patterns (Fig-
ure 6C ; data not shown).
For NB1-sorted MDR1high and MDR1low populations, the follow-
up revealed an increased tumor intake at 100 days after injection in
the MDR1high group compared to the MDR1low and nonsorted
groups, with 50% versus 25% and 20% of mice with adrenal tumors,
respectively (Figure 6A). Although not significant, a faster tumor
growth with MDR1high cells, with larger tumors, was observed com-
pared with MDR1low cells and unsorted population (Figure 6D). His-
tologic observations have been obtained for MDR1high and unsorted
cell–derived tumors (Figure 6E). The MDR1high tumors recapitulated
the cellular morphology of NB1 parental cells with an undifferentiated
morphology, an intermediate MKI without detectable Homer-Wright
rosettes. Likewise, unsorted cells gave rise to orthotopic tumors with
NB1-like undifferentiated morphology, although organized in a more
lobular architecture, with an intermediate MKI. These data suggest
that cells with a higher tumorigenic phenotype, compatible with TICs
characteristics, are enriched within the MDR1high cell subset.
Discussion
The present report describes an original approach to identify and char-
acterize putative TICs in a small, although well-documented panel of
NB tumors. NB metastatic cells, as the most aggressive component
in NB tumor progression, seemed faithful candidates to investigate
self-renewing and tumor-initiating phenotypes. Thus, bone marrow–
derived metastatic cells were used to generate in vivo xenografts as a
continuous source of tumor tissue, further shown to recapitulate the
original tumor phenotype.
Serial sphere generation, a well-established assay for self-renewal
[53–55], could only be obtained from NB stage 4–derived metastatic
cells, thus establishing a significant correlation between high-risk
NB tumors cells and their capacity of long-term survival as spheres.
However, the MYCN expression status was not related to the sphere-
forming capacity of the tumor cells, whereas c-MYC seemed highly ex-
pressed in NB1 and NB2 tumor cells, which also harbored the highest
passages of spheres in our panel of NB samples. The significance of this
correlation should be determined on a larger panel of patients.
The sphere-forming cells (NB1-s), selected from the highly malig-
nant NB clinical sample (NB1), survived in vitro as high passage
spheres, postulating that NB1 might be highly enriched in stem-like
cancer cells. NB1-s cells showed an enhanced capacity to generate
orthotopic tumors in vivo with an increased tumor intake compared
with NB1 total cells. This differential tumorigenicity was abolished
in heterotopic conditions in the presence of Matrigel and fully lost in
the absence of Matrigel, demonstrating that the adrenal gland, as a
permissive microenvironment, may optimize the TIC phenotype. We
therefore concluded that NB1-s population was significantly enriched
in tumorigenic NB1 cells. In addition, the selective increased resistance
of NB1-s cells to a panel of chemotherapeutic drugs suggests a NB-TIC
role in multidrug resistance.
The self-renewing, tumorigenic, and drug-resistant characteristics of
NB1-s cells were profiled by time course gene expression microarray.
The analysis of gradual gene expression changes occurring through suc-
cessive sphere passages identified a total of 901 upregulated genes in
NB1-s. A significant part of them corresponded to essential attributes
of stemness [20], neural crests development, and NB tumorigenesis.
These results corroborated the enrichment in NB1-s of cells with
stem-like features. High-passage NB1-s cells and neural crest–derived
Figure 4. Gene expression profiling of spheres derived from NB1, a high-risk tumor group. (A) Time course gene expression profiling of
four sphere passages derived from NB1 (NB1-s1 to NB1-s4). (B) Graphs illustrating the two directed analyses: left indicates linear re-
gression; right, «step-genes» analysis of the spheres’ gene expression profiles. (C) Venn diagram illustrating the overlap of upregulated
transcripts obtained in the NB1-s with the published genes expressed in NCCs and NSCs [18,20]. Boxes show the listed selected genes
with a higher increase in spheres (fold change [FC] is indicated). The complete list of genes is available in the Supplementary Materials
and Methods section. (D) Validation of the neurosphere-associated gene profile in NB samples by real-time PCR. The overexpression FC
is expressed by the mean ± SEM from three independent experiments for NB1 and cell lines: two for NB2 and one for NB5. *Samples
where the measured transcripts were already highly expressed in the tumor or the cell line. In three cases with “nd” (i.e., no detection),
the level of the transcript extracted from the secondary spheres was too low to be detected. (E) Flow cytometry analysis of the CD133
and MDR1 cell surface expression, in NB1, NB2, and NB4 tumors (s0) and NB1-C, LAN-1 and SK-N-BE(2)C cell lines and in their derived
secondary sphere (s2). Percentages of positive cells are indicated by means ± SEM of three independent measures.
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stem cells indeed shared a number of upregulated genes, as shown by
overlapping NB1-s–associated genes with published lists of NCSC,
NSC, and NCDC genes.
Interestingly, several NB1-s genes, such as ALDH1A2, LGR5,
CD133, and MDR1, were previously described as CSC markers and
as key players in developmental biology processes [47,48,56]. New
candidate NB-TIC markers, EDNRB and GPR177, have been iden-
tified, and their functional role in the NB-TIC “stem” features is cur-
rently investigated.
In the literature, few NB-TIC gene markers have been reported
[13,16,57]. They include CSCmarkers, CD133, ABCG2,NES (nestin),
and the neural crest marker p75 (CD271). NCSCs markers CD271
and SOX10 were expected to be expressed by NB-TICs. However, al-
though CD271+ and SOX10+ cells were detected in undifferentiated
NB tumors and NB spheres, in contrast to melanoma, another neu-
ral crest–derived tumor [58,59], CD271 surprisingly failed to select
for self-renewing and tumorigenic NB cell populations in NB patient
samples and cell lines (data not shown).
Expression of hematopoietic and B-cell markers CD20, CD24, and
CD34, has been described on NB-TIC lines [13]. In contrast, the
highly tumorigenic NB1-s cells lacked CD20, CD24, or CD34 B-cell
markers (data not shown). However, the phenotype of NB-TICs in
Figure 5. CD133high and MDR1high cells in the NB1 sphere cell population (NB1-s) express distinct markers. (A) Relative mRNA expres-
sion levels of CD133, GPR177, EDRNB, and MDR1 genes in CD133high- versus CD133low-sorted cells from NB1-s cells. (B) Relative
mRNA expression levels of CD133, GPR177, EDRNB, MDR1, ABCA1, and ROBO1 genes in CD133high- versus CD133low-sorted cells
from the dissociated NB1 xenograft tumor. (C) Relative MDR1, ABCA1, CD133, NOTCH3, and ABCA1 genes expression levels in
MDR1high/low-sorted cells from the NB1 dissociated tumor. (D) MDR1 and CD133 coexpression analysis in NB1-dissociated tumor cells
by flow cytometry. The percentage of CD133+MDR1-, CD133+MDR1+, and CD133−MDR1+ is indicated. (E) Relative MDR1, CD133,
EDNRB, and NOTCH3 genes expression levels in the CD133highMDR1low-, CD133lowMDR1high-, and CD133lowMDR1low-sorted cells and
unsorted cells from dissociated NB1 tumor. *P < .05, **P < .01, and ***P < .001, Student’s t test.
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our model has been demonstrated to be clearly neuroblastic. This
validation eliminates the hypothesis of a long-term culture-derived
modification resulting in a bone marrow–derived TIC lines that may
explain the acquisition of different markers (American Association for
Cancer Research 2011 Abstract LB-366).
Seven markers (CD133, MDR1, EDNRB, GPR177, ROBO1,
NOTCH3, and ABCA1) were selected from gene lists’ overlaps as rep-
resentative sphere-associated genes. In particular, we showed that the
multidrug resistance gene MDR1, a marker associated to normal stem
cells and CSCs, was uniformly increased in all spheres derived from the
NB sample collection, even in the absence of any exposure to chemo-
therapeutic drugs. Drug resistance, an innate tumor stem cell’s char-
acteristic, ensures them a long life span [60–63]. The alternative
ABC transporter ABCG2 allows selection of a so-called “side popula-
tion,” a tumor cell fraction enriched in TICs [63]. However, because
no SP could be identified in NB tumor or sphere samples (data not
shown), increased resistance observed in NB1-s cells could likely be
attributed to MDR1 gene overexpression.
Conversely, CD133 expression was also increased in NB1-s but not
in every analyzed sphere derived from NB samples and cell lines.
Despite unclear function, the CD133 receptor emerges as one of the
first described and most frequent gene associated to TICs behavior
[56,64–67]. However, the importance of CD133 as a robust stem cell
marker somehow simultaneously vanished with several recent chal-
lenges on its selectivity for tumorigenic and self-renewing cells [68–72].
Intriguingly, it was not possible to select in the NB1 tumor a unique
cell population coexpressing all sevenmarkers and exclusively recapitulat-
ing the functional TIC’s features. Indeed, we demonstrated an anticor-
relation between the expression of CD133/EDNRB/GPR177/NOTCH3
and MDR1/ABCA1 in NB1 tumor cells and spheres, highlighting the
NB1 sphere cell’s heterogeneity. In essence, at least two NB1-s–selected
cell populations, CD133highMDR1low and CD133lowMDR1high, could
be identified in the NB1 tumor.
When assayed for tumorigenic properties in orthotopic implanta-
tions, the CD133high and CD133low NB1 subpopulations were equally
tumorigenic. CD133 expression was higher in CD133low-derived tu-
mors compared to CD133high-derived tumor, revealing its relative plas-
ticity. Thus, CD133, although identified as a NB1 sphere marker, was
not alone able to select tumorigenic NB1 cell population. This con-
clusion is supported by several recent data, suggesting that CD133 is
not restricted to normal stem cells and CSCs and does not reliably
distinguish melanoma [70] or brain tumor stem cells [71,73,74].
In contrast, the MDR1high NB1 cell subset, with a low CD133 ex-
pression, seemed to be associated to a higher in vivo tumor growth,
Figure 6. CD133high and MDR1high NB1 cells have similar tumorigenicity and showed plastic expression in orthotopic tumors. (A) In vivo
tumorigenicity of CD133high/low- and MDR1high/low-sorted cells. Tumor intake is represented by the fraction and percentage of injected
Swiss nude mice bearing tumors after 100 days. CD133 and MDR1 expression in dissociated mice tumors was determined by flow
cytometry. nd indicates not determined. (B) Macroscopic image of a left adrenal tumor in the CD133pos group. (C) H&E staining of the
NB1 CD133pos-derived orthotopic tumors showing the invasive behavior of the cells (black arrowhead and on the right) in the adrenal
tissue (on the left). (D) In vivo adrenal tumor growth of unsorted MDR1high and MDR1low cells. Mean tumor volumes ± SEM are repre-
sented. (E) H&E staining of NB1 original tumor and orthotopic tumors derived from unsorted and MDR1high NB1 cells.
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suggesting that cells with a higher tumorigenic phenotype, compatible
with TICs characteristics, are comprised within the MDR1high NB1
cell subset.
Our results suggest that NB tumorigenic cells, isolated from meta-
static cell population, correspond to heterogeneous and dynamic cell
subsets, whose phenotypes are strongly dependent on in vitro and
in vivo conditions. Indeed, culture conditions may determine the re-
sulting observed cell phenotype and introduce a bias in the descrip-
tion of stem cell characteristics, as it has been shown recently in a
glioblastoma-initiating cell model [75]. The sphere-forming condi-
tions used in our study were originally designed to sustain both stem-
ness and plasticity (differentiation capacity) of NCCs. Hence, these
conditions may temporarily favor neural crest over other stem cells’
characteristics.
Moreover, the consequent in vivo plasticity of NB-TICs may be
derived from the extreme cellular heterogeneity and plasticity of the
NCCs from which NB originates. Heterogeneous NB cell popula-
tions are actually observed in specific and defined culture media
(sphere or adherent culture media) and niches (primary tumor, sub-
cutaneous, or orthotopic xenografts) at a given time point in the de-
velopment of the original tumor. These conditions are likely to select
and expand particular but not exhaustive or stable stem cell pheno-
types, which may only represent a “snapshot” of the cell’s phenotype
and biology. It therefore addresses the question of the methodologi-
cal reliability of TIC investigations in the NB model [76].
Interestingly, similar conclusions about the dynamic behavior of
tumor-propagating cells have been drawn in melanoma, suggesting
that embryonic-related tumors may reveal similar models of tumor
development and progression [12]. Another controversial report iden-
tified at least three melanoma cell subpopulations, with heterogeneous
combined CD34 and p75 expression, and harboring different self-
renewal and in vivo tumorigenicity [70].
Our data suggest that the selection of NB-TIC subset on the basis
of a single marker is not sufficient to isolate the NB cell population
responsible for tumor initiation and sustained growth. Moreover, be-
cause of their plasticity and the influence of the environment, it is still
unclear to which extent the existence of a NB-TIC “niche” is dependent
on the presence of the NB-TICs themselves. Indeed, the phenotypic
identity of the NB-TICs may shift as the niche changes, and vice versa,
making the NB-TICs identification even more difficult.
Thus, the correlation between the gene expression profile of in vitro
selected sphere-forming cells and the in vivo tumorigenic function rep-
resents a pertinent approach that addresses a malignant proliferative cell
function rather than an unstable cell entity. Such strategy may reveal
a more efficient procedure to target the highest malignant NB subsets
for the development of targeted therapies and definitive eradication of
the tumor.
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Supplementary Materials and Methods
Forward and reverse primers for human sequence amplification by
real-time PCR:
HPRT1: 5′-TGACACTGGCAAAACAATGCA-3′ and 5′-GG-
TCCTTTTCACCAGCAAGCT-3′
CD133: 5′-CATGGCAACAGCGATCAAG-3′ and 5′-AGCA-
CAGAGGGTCATTGAG-3′
MDR1: 5′-TTCTGGGAAGAT-3′ and 5′-TATGGTACCT-
GCAAACTCTG-3′
EDNRB: 5′-CGAAACGGTCCCAATATC-3′ and 5′-CCA-
GCTTACACATCTCAG-3′
NOTCH3 : 5 ′ -AGTGGCGACCTCACTTACGACT
GTGCCTGTC-3′ and 5′-GGGCACTGGCAGTTATAG-3′
GPR177: 5′-CTGGATGCTGCTGTTTGG-3′ and 5′-TAC-
CCTGCGATGTGGTTC-3′
ROBO1: 5′-TTGCTTTGGGACGGACTG-3′ and 5′-ATCG-
GCTGGATGACTGTG-3′
ABCA1: 5′-GACATCCTGAAGCCAATC-3′ and 5′-AGAG-
TCCCAAGACTATGC-3′
Figure W1. N-myc and c-myc expression in NB samples of Table 1.
Whole-cell extracts were analyzed by immunoblot analysis for the
presence of N-myc and c-myc in NB1 to NB10 tumor samples and
the NB1-C cell line. The IMR32 cell line was used as a positive con-
trol for N-myc expression. β-Actin was used as a loading control.
NB3 and NB10 signals, obtained in the c-myc immunoblot, have a
higher molecular weigh and therefore are not specific.
Table W2. List of Genes Upregulated or Downregulated in the NB-s Cells and Involved in Stem Cell Physiology.
Category Genes
I. Signaling
Active JAK/STAT ( Janus kinase/signal transducers and
activators of transcription)
Å IL10 receptor beta (×2.3), IL6 signal transducer (×2.4), STAMBPL1 interacting with the adaptor STAM (×2.3)
↓ STATIP1 (×2.2) interacting with STAT3 (×5.2), PIAS (×3.2) inhibitor of activated STAT3, AKT2 (×2.4), SOS2 (×3.5) activator
of MAPK, MYBP2 (×2.7) interacting with c-Myc, PIM genetic target (×2.6)
TGF-β Å TGF-β induced transcript (×3.5), TGF-β receptor 2 (×4.7), SMAD6 (×2.6), SMAD3 (×2.7), BMP5 (×7.3), ID4 (×14.4)
↓ SMAD2 (×2.0), SMURF2 (×2.1), ACVR2B (×2.3), ROCK (×2.2)
Notch Å NOTCH2 (×14.5), NOTCH3 (×6.8), HES1 (×2.8), HEY1 (×2.8), JAG1 (×2.3), MEGF10 (×8.3), MAML2 (×3.8)
↓ HDAC9 (×24.8), MAML3 (×5.5), RBPSUH (×2.2)
Wnt Å WNT5A (×25.0), FZD2 (×2.5), FZD7 (×3.1), FZD6 (×3.2), SNAI2 (×9.0), GPR177 (×10.2), DKK2 (×2.6), TCF7L1 (×14.0),
TCF7L2 (2.1), BMP4 (×4.0), PPARD (×2.4)
↓ cyclinD1 (×4.2)
II. Capacity to sense growth hormone
IGF Å IGFBP3 (×10.8), IGFBP5 (×8.1), IGFBP7 (×9.0), IGF2BP2 (×18.6), IGF2R (×2.3)
↓ IGF2BP3 (×2.2)
FGF Å FGFR1 (×2.7), FGFR2 (×2.7)
↓ FGF9 (×2.1)
EGF Å EGFR (×7.2)
VEGF Å VEGFC (×8.6)
↓ VEGFD (×8.3)
PDGF Å PDGFRL (×3.1), PDGFRA (×3.2), PDGFD (×16.0), PDGFC (×5.0)
PGF ↓ PGF (×2.0)
III. Integrin signaling pathway Å ITGAV (×2.9), ITGA9 (×9.6), RHOJ (×61.3), RELN (×3.3)
↓ ITGA8 (×2.9), JUND (×2.1), JUNB (×2.6), MAPK8 (×2.5), ROCK1 (×2.2)
IV. Neural crest development and NB tumorigenesis Å EPHA4 (×3.5), EPHA5 (×25.6), EPHA6 (×2.7), EFNB2 (×2.6), EFNA4 (×9.3), SEMA3C (×29.0), SPON1 (×24.4), COL9A3
(×2.5), COL12A1 (×2.5), FOXO1A (×3.2), FOXP4 (×3.2), FOXC1 (×9.4), ETS1 (×3.5), SOX9 (×4.8), RET (×4.4), NTRK2
(×13.5), LAMA1 (×12.8), LAMA2 (×5.2), LAMC1 (×2.8), ABCB1 (×6.4), ABCA1 (×16.6), ABCB4 (×9.2), CASP8 (×2.0)
↓ EPHA5 (×9.2), EFNA5 (×4.3), SEMA3E (×4.4), FOXP1 (×3.1), FOXO3A (×3.0), CXCR4 (×2.4), NTRK3 (×2.0), PHOX2A (×3.5),
CD44 (×3.6), BCL2 (×2.3)
Fold changes measured in the microarray analysis of NB1-s cells are indicated for the upregulated (in bold) and downregulated genes.
